Decisional tool to aid portfolio selection decisions into new biotherapeutic modalities

Lead Research Organisation: University College London
Department Name: Biochemical Engineering


The research entails using decision-making modelling techniques to assess the costs, rewards and risks associated with the introduction of new biopharmaceutical products into a company's portfolio, specifically in this case AstraZeneca. Much of the work will involve applying these modelling techniques to novel therapies that treat serious and life-threatening illnesses. Some of the key aims and objectives of this project are to create a tool to evaluate the process economics of some of these newer therapies against AstraZeneca's current product portfolio. The benefit of this is that it will allow for a comparison and inevitably identification of how best approach the manufacture of these new therapies, in the most cost-effective manner possible, so as to reduce the cost of the therapy to patients. It also will allow for this identification to happen earlier on in the process development, enabling a reduction in the typical drug development timescale, thus allowing it to be available to patients sooner. Fundamentally, the overarching aim is to put in place a tool that successfully incorporates multiple criteria (including economic considerations and operational considerations) to identify and optimise the composition of AstraZeneca's drug portfolio.

The work carried out in this project has the potential to be applied to a variety of biopharmaceutical product portfolio situations, whereby other companies that wish to develop vital therapies to rapidly and efficiently treat patients can utilise some of the tools put in place. This will allow for early identification of the options, thus ensuring the therapies are marketed (and so can be used) quicker and are more cost effective than before.


10 25 50

Studentship Projects

Project Reference Relationship Related To Start End Student Name
EP/S021868/1 01/10/2019 31/03/2028
2247004 Studentship EP/S021868/1 23/09/2019 22/09/2023 Annabel Jemima Lyle